News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

|Videos|October 16, 2020

How New and Emerging Trends in CAR T-Cell Therapy Can Affect Your Patients

Author(s)David L. Porter, MD, University of Pennsylvania, Jason Westin, MD, MS, FACP, MD Anderson Cancer Center, Elizabeth Budde, MD, PhD

Episodes in this series

EP. 1 How New and Emerging Trends in CAR T-Cell Therapy Can Affect Your Patients

EP. 1 How New and Emerging Trends in CAR T-Cell Therapy Can Affect Your Patients

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related to this article

Gastric/GEJ Adenocarcinoma | Image Credit: © Ashling Wahner & MJH Life Sciences Using AI

June 22nd, 2026

China’s NMPA Approves First CAR T-Cell Therapy for CLDN18.-2+, HER2– Advanced Gastric/GEJ Adenocarcinoma

China’s NMPA has satri-cel for pretreated, CLDN18.2-positive, HER2-negative advanced gastric/GEJ adenocarcinoma.

Trending on OncLive

June’s GI Rewind: CRC, Gastric Cancer See Several “Firsts” With FDA Review of Adjuvant IO, Global Approval of BRAF-Targeted and CAR T-Cell Therapies

Namodenoson Meets Safety End Point in PDAC, Shows Durable Survival Outcomes Pretreated Subgroup

FDA Approval Positions Belzutifan Plus Pembrolizumab as a New Adjuvant Standard in ccRCC

Taking Science from Bench to Bedside to the Block – Introducing Dr. Robert A. Winn

SERENA-6 Controversies Push the Breast Cancer Field to Consider the Future Role of ctDNA-Guided Treatment Decisions